Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 46
Filter
1.
Carbohydr Polym ; 312: 120756, 2023 Jul 15.
Article in English | MEDLINE | ID: covidwho-2309426

ABSTRACT

In this study, we developed a new filtering bioaerogel based on linear polyvinyl alcohol (PVA) and the cationic derivative of chitosan (N-[(2-hydroxy-3-trimethylamine) propyl] chitosan chloride, HTCC) with a potential antiviral application. A strong intermolecular network architecture was formed thanks to the introduction of linear PVA chains, which can efficiently interpenetrate the glutaraldehyde(GA)-crosslinked HTCC chains. The morphology of the obtained structures was examined using scanning electron microscopy (SEM) and atomic force microscopy (AFM). The aerogels and modified polymers' elemental composition (including the chemical environment) was determined using X-ray photoelectron spectroscopy (XPS). New aerogels with more than twice as much developed micro- and mesopore space and BET-specific surface area were obtained concerning the starting sample chitosan aerogel crosslinked by glutaraldehyde (Chit/GA). The results obtained from the XPS analysis showed the presence of cationic 3-trimethylammonium groups on the surface of the aerogel, which can interact with viral capsid proteins. No cytotoxic effect of HTCC/GA/PVA aerogel was also observed on fibroblast cells of the NIH3T3 line. Furthermore, the HTCC/GA/PVA aerogel has been shown that efficiently traps mouse hepatitis virus (MHV) from suspension. The presented concept of aerogel filters for virus capture based on modified chitosan and polyvinyl alcohol has a high application potential.


Subject(s)
Chitosan , Viruses , Animals , Mice , Chitosan/chemistry , Polyvinyl Alcohol/chemistry , Glutaral/chemistry , NIH 3T3 Cells
2.
Viruses ; 15(3)2023 02 28.
Article in English | MEDLINE | ID: covidwho-2289102

ABSTRACT

Current antiviral therapy research is focused on developing dosage forms that enable highly effective drug delivery, providing a selective effect in the organism, lower risk of adverse effects, a lower dose of active pharmaceutical ingredients, and minimal toxicity. In this article, antiviral drugs and the mechanisms of their action are summarized at the beginning as a prerequisite background to develop relevant drug delivery/carrier systems for them, classified and briefly discussed subsequently. Many of the recent studies aim at different types of synthetic, semisynthetic, and natural polymers serving as a favorable matrix for the antiviral drug carrier. Besides a wider view of different antiviral delivery systems, this review focuses on advances in antiviral drug delivery systems based on chitosan (CS) and derivatized CS carriers. CS and its derivatives are evaluated concerning methods of their preparation, their basic characteristics and properties, approaches to the incorporation of an antiviral drug in the CS polymer as well as CS nanoparticulate systems, and their recent biomedical applications in the context of actual antiviral therapy. The degree of development (i.e., research study, in vitro/ex vivo/in vivo preclinical testing), as well as benefits and limitations of CS polymer and CS nanoparticulate drug delivery systems, are reported for particular viral diseases and corresponding antivirotics.


Subject(s)
Chitosan , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , Drug Delivery Systems , Drug Carriers , Polymers
3.
Int J Biol Macromol ; 236: 123951, 2023 May 01.
Article in English | MEDLINE | ID: covidwho-2276638

ABSTRACT

Masks proved to be necessary protective measure during the COVID-19 pandemic, but they provided a physical barrier rather than inactivating viruses, increasing the risk of cross-infection. In this study, high-molecular weight chitosan and cationised cellulose nanofibrils were screen-printed individually or as a mixture onto the inner surface of the first polypropylene (PP) layer. First, biopolymers were evaluated by various physicochemical methods for their suitability for screen-printing and antiviral activity. Second, the effect of the coatings was evaluated by analysing the morphology, surface chemistry, charge of the modified PP layer, air permeability, water-vapour retention, add-on, contact angle, antiviral activity against the model virus phi6 and cytotoxicity. Finally, the functional PP layers were integrated into face masks, and resulting masks were tested for wettability, air permeability, and viral filtration efficiency (VFE). Air permeability was reduced for modified PP layers (43 % reduction for kat-CNF) and face masks (52 % reduction of kat-CNF layer). The antiviral potential of the modified PP layers against phi6 showed inhibition of 0.08 to 0.97 log (pH 7.5) and cytotoxicity assay showed cell viability above 70 %. VFE of the masks remained the same (~99.9 %), even after applying the biopolymers, confirming that these masks provided high level of protection against viruses.


Subject(s)
COVID-19 , Chitosan , Humans , COVID-19/prevention & control , Antiviral Agents/pharmacology , Pandemics/prevention & control , Cellulose/pharmacology , Masks
4.
Sci Rep ; 13(1): 4401, 2023 03 16.
Article in English | MEDLINE | ID: covidwho-2258067

ABSTRACT

Chitosan nanoparticles (CNPs) are promising biopolymeric nanoparticles with excellent physicochemical, antimicrobial, and biological properties. CNPs have a wide range of applications due to their unique characteristics, including plant growth promotion and protection, drug delivery, antimicrobials, and encapsulation. The current study describes an alternative, biologically-based strategy for CNPs biosynthesis using Olea europaea leaves extract. Face centered central composite design (FCCCD), with 50 experiments was used for optimization of CNPs biosynthesis. The artificial neural network (ANN) was employed for analyzing, validating, and predicting CNPs biosynthesis using Olea europaea leaves extract. Using the desirability function, the optimum conditions for maximum CNPs biosynthesis were determined theoretically and verified experimentally. The highest experimental yield of CNPs (21.15 mg CNPs/mL) was obtained using chitosan solution of 1%, leaves extract solution of 100%, initial pH 4.47, and incubation time of 60 min at 53.83°C. The SEM and TEM images revealed that CNPs had a spherical form and varied in size between 6.91 and 11.14 nm. X-ray diffraction demonstrates the crystalline nature of CNPs. The surface of the CNPs is positively charged, having a Zeta potential of 33.1 mV. FTIR analysis revealed various functional groups including C-H, C-O, CONH2, NH2, C-OH and C-O-C. The thermogravimetric investigation indicated that CNPs are thermally stable. The CNPs were able to suppress biofilm formation by P. aeruginosa, S. aureus and C. albicans at concentrations ranging from 10 to 1500 µg/mL in a dose-dependent manner. Inhibition of biofilm formation was associated with suppression of metabolic activity, protein/exopolysaccharide moieties, and hydrophobicity of biofilm encased cells (r ˃ 0.9, P = 0.00). Due to their small size, in the range of 6.91 to 11.14 nm, CNPs produced using Olea europaea leaves extract are promising for applications in the medical and pharmaceutical industries, in addition to their potential application in controlling multidrug-resistant microorganisms, especially those associated with post COVID-19 pneumonia in immunosuppressed patients.


Subject(s)
Anti-Infective Agents , COVID-19 , Chitosan , Nanoparticles , Humans , Chitosan/chemistry , Artificial Intelligence , Staphylococcus aureus , Nanoparticles/chemistry , Anti-Infective Agents/pharmacology
5.
Int J Biol Macromol ; 231: 123587, 2023 Mar 15.
Article in English | MEDLINE | ID: covidwho-2232256

ABSTRACT

The worldwide outbreak of SARS-CoV-2 has attracted extensive attention to antibacterial and antivirus materials. Cellulose is the most potential candidate for the preparation of green, environmentally friendly antibacterial and antiviral materials. Herein, modified cellulosic fibers with sustained antibacterial and antiviral performance was prepared by introducing chitosan oligosaccharide onto the fibers. The two-step method is proved to be more effective than the one-step method for enhanced chitosan oligosaccharide loadings and antibacterial and antiviral activity. In this instance, the modified fibers with 61.77 mg/g chitosan oligosaccharide loadings can inhibit Staphylococcus aureus and Escherichia coli by 100 % after contacting with bacteria for 12 h and reduce the bacteriophage MS2 by 99.19 % after 1 h of contact. More importantly, the modified fibers have washing durable antibacterial and antiviral activity; the modified fibers have 100 % antibacterial and 98.38 % antiviral activity after 20 washing cycles. Benefiting from the excellent performance of the individual fibers, the paper prepared from the modified fibers show great antibacterial (100 %) and antiviral performance (99.01 %) and comparable mechanical strength. The modified fibers have potential applications in the manufacture of protective clothing and protective hygiene products.


Subject(s)
COVID-19 , Chitosan , Humans , Chitosan/pharmacology , SARS-CoV-2 , Anti-Bacterial Agents/pharmacology , Escherichia coli , Oligosaccharides
6.
J Microencapsul ; 40(4): 217-232, 2023 Jun.
Article in English | MEDLINE | ID: covidwho-2230983

ABSTRACT

Azithromycin is an antibiotic proposed as a treatment for the coronavirus disease 2019 (COVID-19) due to its immunomodulatory activity. The aim of this study is to develop dry powder formulations of azithromycin-loaded poly(lactic-co-glycolic acid) (PLGA) nanocomposite microparticles for pulmonary delivery to improve the low bioavailability of azithromycin. Double emulsion method was used to produce nanoparticles, which were then spray dried to form nanocomposite microparticles. Encapsulation efficiency and drug loading were analysed, and formulations were characterised by particle size, zeta potential, morphology, crystallinity and in-vitro aerosol dispersion performance. The addition of chitosan changed the neutrally-charged azithromycin only formulation to positively-charged nanoparticles. However, the addition of chitosan also increased the particle size of the formulations. It was observed in the NGI® data that there was an improvement in dispersibility of the chitosan-related formulations. It was demonstrated in this study that all dry powder formulations were able to deliver azithromycin to the deep lung regions, which suggested the potential of using azithromycin via pulmonary drug delivery as an effective method to treat COVID-19.


Subject(s)
COVID-19 , Chitosan , Nanoparticles , Humans , Azithromycin , Powders , Administration, Inhalation , COVID-19 Drug Treatment , Respiratory Aerosols and Droplets , Particle Size
7.
Biosensors (Basel) ; 13(1)2022 Dec 28.
Article in English | MEDLINE | ID: covidwho-2236357

ABSTRACT

In this work, we report on the development of a simple electrochemical immunosensor for the detection of D-dimer protein in human plasma samples. The immunosensor is built by a simple drop-casting procedure of chitosan nanoparticles (CSNPs) as biocompatible support, Protein A (PrA), to facilitate the proper orientation of the antibody sites to epitopes as a capture biomolecule, and the D-dimer antibody onto a carboxyl functionalized multi-walled carbon nanotubes screen printed electrode (MWCNTs-SPE). The CSNPs have been morphologically characterized by Scanning Electron Microscopy (SEM) and Dynamic Light Scattering (DLS) techniques. Successively, the electrochemical properties of the screen-printed working electrode after each modification step have been characterized by differential pulse voltammetry (DPV) and electrochemical impedance spectroscopy (EIS). The resulting MWCNTs-CSNPs-PrA-D-dimer Ab immunosensor displays an optimal and promising platform for antibody immobilization and specific D-dimer detection. DPV has been used to investigate the antigen/antibody interaction at different D-dimer concentrations. The proposed voltammetric immunosensor allowed a linear range from 2 to 500 µg L-1 with a LOD of 0.6 µg L-1 and a sensitivity of 1.3 µA L µg-1 cm-2. Good stability and a fast response time (5 s) have been reported. Lastly, the performance of the voltammetric immunosensor has been tested in human plasma samples, showing satisfactory results, thus attesting to the promising feasibility of the proposed platform for detecting D-dimer in physiological samples.


Subject(s)
Biosensing Techniques , COVID-19 , Chitosan , Metal Nanoparticles , Nanotubes, Carbon , Humans , Biosensing Techniques/methods , Nanotubes, Carbon/chemistry , Immunoassay , COVID-19/diagnosis , Biomarkers , Prognosis , Antibodies , Metal Nanoparticles/chemistry , Electrodes , Chitosan/chemistry , Electrochemical Techniques , Limit of Detection , Gold/chemistry
8.
Int J Mol Sci ; 24(2)2023 Jan 07.
Article in English | MEDLINE | ID: covidwho-2166608

ABSTRACT

The severity of COVID-19 commonly depends on age-related tissue stiffness. The aim was to review publications that explain the effect of microenvironmental extracellular matrix stiffness on cellular processes. Platelets and endothelial cells are mechanosensitive. Increased tissue stiffness can trigger cytokine storm with the upregulated expression of pro-inflammatory cytokines, such as tumor necrosis factor alpha and interleukin IL-6, and tissue integrity disruption, leading to enhanced virus entry and disease severity. Increased tissue stiffness in critically ill COVID-19 patients triggers platelet activation and initiates plague formation and thrombosis development. Cholesterol content in cell membrane increases with aging and further enhances tissue stiffness. Membrane cholesterol depletion decreases virus entry to host cells. Membrane cholesterol lowering drugs, such as statins or novel chitosan derivatives, have to be further developed for application in COVID-19 treatment. Statins are also known to decrease arterial stiffness mitigating cardiovascular diseases. Sulfated chitosan derivatives can be further developed for potential use in future as anticoagulants in prevention of severe COVID-19. Anti-TNF-α therapies as well as destiffening therapies have been suggested to combat severe COVID-19. The inhibition of the nuclear factor kappa-light-chain-enhancer of activated B cells pathway must be considered as a therapeutic target in the treatment of severe COVID-19 patients. The activation of mechanosensitive platelets by higher matrix stiffness increases their adhesion and the risk of thrombus formation, thus enhancing the severity of COVID-19.


Subject(s)
COVID-19 , Chitosan , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Thrombosis , Humans , Endothelial Cells , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Chitosan/therapeutic use , COVID-19 Drug Treatment , Tumor Necrosis Factor Inhibitors/therapeutic use , Thrombosis/drug therapy , Interleukin-6 , Extracellular Matrix , Cholesterol/therapeutic use
9.
Chirality ; 34(9): 1166-1190, 2022 09.
Article in English | MEDLINE | ID: covidwho-2084347

ABSTRACT

Polysaccharides arouse great interest due to their structure and unique properties, such as biocompatibility, biodegradability, and absence of toxicity. Polysaccharides from marine sources are particularly useful due to the wide variety of applications and biological activities. Chitosan, a deacetylated derivative of chitin, is an example of an interesting bioactive marine-derived polysaccharide. Moreover, a wide variety of chemical modifications and conjugation of chitosan with other bioactive molecules are responsible for improvements in physicochemical properties and biological activities, expanding the range of applications. An overview of the synthetic approaches for preparing chitosan, chitosan derivatives, and conjugates is described and discussed. A recent update of the biological activities and applications in different research fields, mainly focused on the last 5 years, is presented, highlighting current trends.


Subject(s)
Chitosan , Chitin/chemistry , Chitosan/chemistry , Chitosan/pharmacology , Polysaccharides/chemistry , Polysaccharides/pharmacology , Stereoisomerism
10.
AAPS PharmSciTech ; 23(7): 267, 2022 Sep 26.
Article in English | MEDLINE | ID: covidwho-2054055

ABSTRACT

Tissue engineering has emerged as an interesting field nowadays; it focuses on accelerating the auto-healing mechanism of tissues rather than organ transplantation. It involves implanting an In Vitro cultured initiative tissue or a scaffold loaded with tissue regenerating ingredients at the damaged area. Both techniques are based on the use of biodegradable, biocompatible polymers as scaffolding materials which are either derived from natural (e.g. alginates, celluloses, and zein) or synthetic sources (e.g. PLGA, PCL, and PLA). This review discusses in detail the recent applications of different biomaterials in tissue engineering highlighting the targeted tissues besides the in vitro and in vivo key findings. As well, smart biomaterials (e.g. chitosan) are fascinating candidates in the field as they are capable of elucidating a chemical or physical transformation as response to external stimuli (e.g. temperature, pH, magnetic or electric fields). Recent trends in tissue engineering are summarized in this review highlighting the use of stem cells, 3D printing techniques, and the most recent 4D printing approach which relies on the use of smart biomaterials to produce a dynamic scaffold resembling the natural tissue. Furthermore, the application of advanced tissue engineering techniques provides hope for the researchers to recognize COVID-19/host interaction, also, it presents a promising solution to rejuvenate the destroyed lung tissues.


Subject(s)
COVID-19 , Chitosan , Zein , Alginates , Biocompatible Materials , Humans , Polyesters , Polymers , Printing, Three-Dimensional , Tissue Engineering/methods , Tissue Scaffolds
11.
Mar Drugs ; 20(8)2022 Aug 18.
Article in English | MEDLINE | ID: covidwho-2023893

ABSTRACT

The increased interest in nanomedicine and its applicability for a wide range of biological functions demands the search for raw materials to create nanomaterials. Recent trends have focused on the use of green chemistry to synthesize metal and metal-oxide nanoparticles. Bioactive chemicals have been found in a variety of marine organisms, including invertebrates, marine mammals, fish, algae, plankton, fungi, and bacteria. These marine-derived active chemicals have been widely used for various biological properties. Marine-derived materials, either whole extracts or pure components, are employed in the synthesis of nanoparticles due to their ease of availability, low cost of production, biocompatibility, and low cytotoxicity toward eukaryotic cells. These marine-derived nanomaterials have been employed to treat infectious diseases caused by bacteria, fungi, and viruses as well as treat non-infectious diseases, such as tumors, cancer, inflammatory responses, and diabetes, and support wound healing. Furthermore, several polymeric materials derived from the marine, such as chitosan and alginate, are exploited as nanocarriers in drug delivery. Moreover, a variety of pure bioactive compounds have been loaded onto polymeric nanocarriers and employed to treat infectious and non-infectious diseases. The current review is focused on a thorough overview of nanoparticle synthesis and its biological applications made from their entire extracts or pure chemicals derived from marine sources.


Subject(s)
Chitosan , Metal Nanoparticles , Nanoparticles , Neoplasms , Noncommunicable Diseases , Animals , Bacteria , Chitosan/chemistry , Drug Delivery Systems , Fungi , Mammals , Metal Nanoparticles/chemistry , Nanoparticles/chemistry , Neoplasms/drug therapy , Noncommunicable Diseases/drug therapy , Pharmaceutical Preparations , Polymers/therapeutic use
12.
Mar Drugs ; 20(8)2022 Jul 25.
Article in English | MEDLINE | ID: covidwho-2023891

ABSTRACT

Nowadays, the therapeutic efficiency of small interfering RNAs (siRNA) is still limited by the efficiency of gene therapy vectors capable of carrying them inside the target cells. In this study, siRNA nanocarriers based on low molecular weight chitosan grafted with increasing proportions (5 to 55%) of diisopropylethylamine (DIPEA) groups were developed, which allowed precise control of the degree of ionization of the polycations at pH 7.4. This approach made obtaining siRNA nanocarriers with small sizes (100-200 nm), positive surface charge and enhanced colloidal stability (up to 24 h) at physiological conditions of pH (7.4) and ionic strength (150 mmol L-1) possible. Moreover, the PEGylation improved the stability of the nanoparticles, which maintained their colloidal stability and nanometric sizes even in an albumin-containing medium. The chitosan-derivatives displayed non-cytotoxic effects in both fibroblasts (NIH/3T3) and macrophages (RAW 264.7) at high N/P ratios and polymer concentrations (up to 0.5 g L-1). Confocal microscopy showed a successful uptake of nanocarriers by RAW 264.7 macrophages and a promising ability to silence green fluorescent protein (GFP) in HeLa cells. These results were confirmed by a high level of tumor necrosis factor-α (TNFα) knockdown (higher than 60%) in LPS-stimulated macrophages treated with the siRNA-loaded nanoparticles even in the FBS-containing medium, findings that reveal a good correlation between the degree of ionization of the polycations and the physicochemical properties of nanocarriers. Overall, this study provides an approach to enhance siRNA condensation by chitosan-based carriers and highlights the potential of these nanocarriers for in vivo studies.


Subject(s)
Chitosan , Nanoparticles , Chitosan/chemistry , HeLa Cells , Humans , Nanoparticles/chemistry , Particle Size , Polyethylene Glycols/chemistry , RNA, Small Interfering/metabolism
13.
Carbohydr Polym ; 296: 119928, 2022 Nov 15.
Article in English | MEDLINE | ID: covidwho-1966409

ABSTRACT

The coating is frequently adopted to modify the product surface without influencing the essential features of the pristine products. Recently, significant demand has existed for efficient anti-fogging/anti-microbial surfaces in various applications to inhibit microbial growth with high transparency in high-humidity environments, especially in pandemics such as COVID-19. The current study used dual-functional chitosan (Ch) polysaccharide coating with highly hydrophilic properties to be progressively incorporated onto the glass substrates using a simple one-pot technique. Utilizing hot/cold fogging tests and plate count method, the dual-functional Ch/SiO2(3) layer possesses excellent antifogging performance and anti-microbial activity. The hydrogen bonds and electrostatic attractions formed between MSN and Ch result in a higher bound water ratio, as confirmed by the low field nuclear magnetic resonance (LF-NMR). Therefore, based on the chitosan/silica layer, 95 % is the minimum proportion of bound water necessary in the final layer structure to completely inhibit microbial and fogging activities.


Subject(s)
Anti-Infective Agents , COVID-19 , Chitosan , Optical Devices , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Anti-Infective Agents/pharmacology , Chitosan/chemistry , Chitosan/pharmacology , Humans , Silicon Dioxide , Water
14.
Sci Rep ; 12(1): 8118, 2022 05 17.
Article in English | MEDLINE | ID: covidwho-1931463

ABSTRACT

In the current COVID-19 pandemic, the next generation of innovative materials with enhanced anti-SARS-CoV-2 activity is urgently needed to prevent the spread of this virus within the community. Herein, we report the synthesis of chitosan/α-Ag2WO4 composites synthetized by femtosecond laser irradiation. The antimicrobial activity against Escherichia coli, Methicilin-susceptible Staphylococcus aureus (MSSA), and Candida albicans was determined by estimating the minimum inhibitory concentration (MIC) and minimal bactericidal/fungicidal concentration (MBC/MFC). To assess the biocompatibility of chitosan/α-Ag2WO4 composites in a range involving MIC and MBC/MFC on keratinocytes cells (NOK-si), an alamarBlue™ assay and an MTT assay were carried out. The SARS-CoV-2 virucidal effects was analyzed in Vero E6 cells through viral titer quantified in cell culture supernatant by PFU/mL assay. Our results showed a very similar antimicrobial activity of chitosan/α-Ag2WO4 3.3 and 6.6, with the last one demonstrating a slightly better action against MSSA. The chitosan/α-Ag2WO4 9.9 showed a wide range of antimicrobial activity (0.49-31.25 µg/mL). The cytotoxicity outcomes by alamarBlue™ revealed that the concentrations of interest (MIC and MBC/MFC) were considered non-cytotoxic to all composites after 72 h of exposure. The Chitosan/α-Ag2WO4 (CS6.6/α-Ag2WO4) composite reduced the SARS-CoV-2 viral titer quantification up to 80% of the controls. Then, our results suggest that these composites are highly efficient materials to kill bacteria (Escherichia coli, Methicillin-susceptible Staphylococcus aureus, and the yeast strain Candida albicans), in addition to inactivating SARS-CoV-2 by contact, through ROS production.


Subject(s)
COVID-19 , Chitosan , Escherichia coli Infections , Staphylococcal Infections , Anti-Bacterial Agents/pharmacology , Candida albicans , Chitosan/pharmacology , Escherichia coli , Humans , Lasers , Microbial Sensitivity Tests , Pandemics , SARS-CoV-2 , Staphylococcus aureus
15.
J Appl Microbiol ; 133(2): 1089-1098, 2022 Aug.
Article in English | MEDLINE | ID: covidwho-1840447

ABSTRACT

AIMS: The discovery of antiviral substances to respond to COVID-19 is a global issue, including the field of drug development based on natural materials. Here, we showed that chitosan-based substances have natural antiviral properties against SARS-CoV-2 in vitro. METHODS AND RESULTS: The molecular weight of chitosan-based substances was measured by the gel permeation chromatography analysis. In MTT assay, the chitosan-based substances have low cytotoxicity to Vero cells. The antiviral effect of these substances was confirmed by quantitative viral RNA targeting the RdRp and E genes and plaque assay. Among the substances tested, low molecular weight chitooligosaccharide decreased the fluorescence intensity of SARS-CoV-2 nucleocapsid protein of the virus-infected cells in a dose-dependent manner. CONCLUSIONS: In conclusion, the chitooligosaccharide, a candidate for natural treatment, has antiviral effects against the SARS-CoV-2 virus in vitro. SIGNIFICANCE AND IMPACT OF STUDY: In this study, it was suggested for the first time that chitosan-based substances such as chitooligosaccharide can have an antiviral effect on SARS-CoV-2 in vitro.


Subject(s)
COVID-19 Drug Treatment , Chitosan , Animals , Antiviral Agents/pharmacology , Chitosan/pharmacology , Chlorocebus aethiops , Molecular Weight , Oligosaccharides , SARS-CoV-2 , Vero Cells
16.
J Immunol ; 208(6): 1396-1405, 2022 03 15.
Article in English | MEDLINE | ID: covidwho-1818327

ABSTRACT

To develop a safe and effective nanoparticle (NP) multiepitope DNA vaccine for controlling infectious bronchitis virus (IBV) infection, we inserted the multiepitope gene expression box SBNT into a eukaryotic expression vector pcDNA3.1(+) to construct a recombinant plasmid pcDNA/SBNT. The NP multiepitope DNA vaccine pcDNA/SBNT-NPs were prepared using chitosan to encapsulate the recombinant plasmid pcDNA/SBNT, with a high encapsulation efficiency of 94.90 ± 1.35%. These spherical pcDNA/SBNT-NPs were 140.9 ± 73.2 nm in diameter, with a mean ζ potential of +16.8 ± 4.3 mV. Our results showed that the chitosan NPs not only protected the plasmid DNA from DNase degradation but also mediated gene transfection in a slow-release manner. Immunization with pcDNA/SBNT-NPs induced a significant IBV-specific immune response and partially protected chickens against homologous IBV challenge. Therefore, the chitosan NPs could be a useful gene delivery system, and NP multiepitope DNA vaccines may be a potential alternative for use in the development of a novel, safe, and effective IBV vaccine.


Subject(s)
Chitosan , Coronavirus Infections , Infectious bronchitis virus , Nanoparticles , Vaccines, DNA , Viral Vaccines , Animals , Chickens , Coronavirus Infections/prevention & control , Infectious bronchitis virus/genetics , Vaccines, DNA/genetics
17.
Carbohydr Polym ; 290: 119500, 2022 Aug 15.
Article in English | MEDLINE | ID: covidwho-1797107

ABSTRACT

The coronavirus pandemic, COVID-19 has a global impact on the lives and livelihoods of people. It is characterized by a widespread infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), where infected patients may develop serious medical complications or even face death. Development of therapeutic is essential to reduce the morbidity and mortality of infected patients. Chitosan is a versatile biomaterial in nanomedicine and exhibits anti-microbial, anti-cancer and immunomodulatory properties. This review highlights the progress in chitosan design and application pertaining to the anti-viral effects of chitosan and chitosan derivatives (hydroxypropyl trimethylammonium, sulfate, carboxymethyl, bromine, sialylglycopolymer, peptide and phosphonium conjugates) as a function of molecular weight, degree of deacetylation, type of substituents and their degree and site of substitution. The physicochemical attributes of these polymeric therapeutics are identified against the possibility of processing them into nanomedicine which can confer a higher level of anti-viral efficacy. The designs of chitosan for the purpose of targeting SARS-CoV-2, as well as the ever-evolving strains of viruses with a broad spectrum anti-viral activity to meet pandemic preparedness at the early stages of outbreak are discussed.


Subject(s)
COVID-19 Drug Treatment , Chitosan , Antiviral Agents/chemistry , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , Chitosan/chemistry , Humans , Nanomedicine , SARS-CoV-2
18.
ACS Appl Mater Interfaces ; 14(16): 18989-19001, 2022 Apr 27.
Article in English | MEDLINE | ID: covidwho-1795857

ABSTRACT

Antibacterial air filtration membranes are essential for personal protection during the pandemic of coronavirus disease 2019 (COVID-19). However, high-efficiency filtration with low pressure drop and effective antibiosis is difficult to achieve. To solve this problem, an innovative electrospinning system with low binding energy and high conductivity was built to enhance the jet splitting, and a fluffy nanofibrous membrane containing numerous ultrafine nanofibers and large quantities of antibacterial agents was achieved, which was fabricated by electrospinning polyamide 6 (PA6), poly(vinyl pyrrolidone) (PVP), chitosan (CS), and curcumin (Cur). The filtration efficiency for 0.3 µm NaCl particles was 99.83%, the pressure drop was 54 Pa, and the quality factor (QF) was up to 0.118 Pa-1. CS and Cur synergistically enhanced the antibacterial performance; the bacteriostatic rates against Escherichia coli and Staphylococcus aureus were 99.5 and 98.9%, respectively. This work will largely promote the application of natural antibacterial agents in the development of high-efficiency, low-resistance air filters for personal protection by manufacturing ultrafine nanofibers with enhanced antibiosis.


Subject(s)
Air Filters , COVID-19 Drug Treatment , Chitosan , Curcumin , Nanofibers , Anti-Bacterial Agents/pharmacology , Chitosan/pharmacology , Curcumin/pharmacology , Escherichia coli , Filtration , Humans , Nanofibers/chemistry
19.
Biomacromolecules ; 23(4): 1812-1825, 2022 04 11.
Article in English | MEDLINE | ID: covidwho-1764110

ABSTRACT

Cowpea mosaic virus (CPMV) is a potent immunogenic adjuvant and epitope display platform for the development of vaccines against cancers and infectious diseases, including coronavirus disease 2019. However, the proteinaceous CPMV nanoparticles are rapidly degraded in vivo. Multiple doses are therefore required to ensure long-lasting immunity, which is not ideal for global mass vaccination campaigns. Therefore, we formulated CPMV nanoparticles in injectable hydrogels to achieve slow particle release and prolonged immunostimulation. Liquid formulations were prepared from chitosan and glycerophosphate (GP) before homogenization with CPMV particles at room temperature. The formulations containing high-molecular-weight chitosan and 0-4.5 mg mL-1 CPMV gelled rapidly at 37 °C (5-8 min) and slowly released cyanine 5-CPMV particles in vitro and in vivo. Importantly, when a hydrogel containing CPMV displaying severe acute respiratory syndrome coronavirus 2 spike protein epitope 826 (amino acid 809-826) was administered to mice as a single subcutaneous injection, it elicited an antibody response that was sustained over 20 weeks, with an associated shift from Th1 to Th2 bias. Antibody titers were improved at later time points (weeks 16 and 20) comparing the hydrogel versus soluble vaccine candidates; furthermore, the soluble vaccine candidates retained Th1 bias. We conclude that CPMV nanoparticles can be formulated effectively in chitosan/GP hydrogels and are released as intact particles for several months with conserved immunotherapeutic efficacy. The injectable hydrogel containing epitope-labeled CPMV offers a promising single-dose vaccine platform for the prevention of future pandemics as well as a strategy to develop long-lasting plant virus-based nanomedicines.


Subject(s)
COVID-19 , Chitosan , Comovirus , Plant Viruses , Vaccines , Animals , COVID-19/prevention & control , COVID-19 Vaccines , Delayed-Action Preparations/pharmacology , Epitopes , Humans , Hydrogels , Mice , Spike Glycoprotein, Coronavirus
20.
Int J Nanomedicine ; 16: 8141-8158, 2021.
Article in English | MEDLINE | ID: covidwho-1581579

ABSTRACT

Chitosan has been investigated in several biological fields, including drug and gene delivery, tissue engineering antiviral and immunological adjuvant methods. It's a cationic copolymer of N-acetyl glucosamine and D-glucosamine with different molecular chain lengths, compositions, and sequences than N-acetyl glucosamine and D-glucosamine. It is biocompatible and cyto-compatible, as well as recyclable and bioresorbable. As effective drug delivery methods, chitosan nanoparticles are shaped into several pathways. The purpose of this article is to provide an overview of its antiviral application as a nanocarrier for antiviral medications, highlighting the benefits, limitations, and downsides. In this review, we will report the most recent COVID-19 vaccination advances. It will also be discussed what the future holds for chitosan nanoparticles in the treatment of coronaviruses.


Subject(s)
COVID-19 Drug Treatment , Chitosan , Nanoparticles , Antiviral Agents , COVID-19 Vaccines , Drug Carriers , Drug Delivery Systems , Humans , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL